Clinical Trial Detail

NCT ID NCT01064479
Title Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

head and neck squamous cell carcinoma

Therapies

Erlotinib

Carboplatin

Docetaxel

Cisplatin

Age Groups: adult

No variant requirements are available.